Spondyloarthritis & psoriatic arthritis
Examining the role of dipeptidyl peptidase IV (DPPIV) in psoriatic disease
Main findingResult — go to the resultr −0.27Authors' conclusion
Our exploratory findings suggest that DPPIV SF levels may be an important indicator of joint inflammation in PsA patients. In PsA patients, DPPIV may be associated with MTX response. CXCL10 may be regulated post translationally by DPPIV.
Study context
- Population
- Patients with PsA, psoriasis without arthritis, OA and healthy controls
- Participants
- 80 / 80 / 40 / 40 / 14 / 14
- Exposure
- DPPIV, CXCL10 and DPPIV enzyme activity (EA) in PsA vs PsC vs OA vs healthy controls (HC), and in PsA before vs after MTX
- PsAn = 80
- PsCn = 80
- HCn = 40reference
- MTXn = 40
- PsA SFn = 14
- OAn = 14reference
- Outcome
- Levels of DPPIV, CXCL10 and DPPIV EA
Methodological detailsexploratory, longitudinal MTX sub-cohort (before and after 24 weeks), sex-matched OA comparison for SF
- Exploratory
- Longitudinal MTX sub-cohort (before and after 24 weeks)
- Sex-matched OA comparison for SF
Main finding
As reported in the abstract
r
−0.27
P = 0.02
Observational data: associations, not effects.
Original publication
Examining the role of dipeptidyl peptidase IV (DPPIV) in psoriatic disease. Rheumatology (Oxford). Published 11 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →